Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Joel Greenblatt defined Return on Capital differently in his book The Little Book That Still Beats the Market (Little Books. Big Profits). He defines ROC (Joel Greenblatt) % as EBIT divided by the total of Property, Plant and Equipment and net working capital. Guangzhou Kingmed Diagnostics Group Co's annualized ROC (Joel Greenblatt) % for the quarter that ended in Mar. 2026 was 6.88%.
SHSE:603882'
s ROC (Joel Greenblatt) % Range Over the Past 10 Years
Min: -8.38 Med: 26.09 Max: 100.44
Current: -1.69
During the past 13 years, Guangzhou Kingmed Diagnostics Group Co's highest ROC (Joel Greenblatt) % was 100.44%. The lowest was -8.38%. And the median was 26.09%.
SHSE:603882's ROC (Joel Greenblatt) % is ranked better than 50% of 210
companies
in the Medical Diagnostics & Research industry
Industry Median: -2.15
vs SHSE:603882: -1.69
Guangzhou Kingmed Diagnostics Group Co (SHSE:603882) ROC (Joel Greenblatt) % Explanation
The way Joel Greenblatt defines Return on Capital is a more accurate measure of how efficiently the company generates returns onthe capital actually invested in the business. EBIT is used instead of net income because the tax and interest payment may be affected by factors other than the core business operation. Intangible assets are not included in the calculation because they don't need to be replaced.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Guangzhou Kingmed Diagnostics Group Co ROC (Joel Greenblatt) % Chart
Guangzhou Kingmed Diagnostics Group Co Annual Data
SHSE:603882 vs TMO, DHR, IDXX: ROC (Joel Greenblatt) % Comparison
For the Diagnostics & Research subindustry, Guangzhou Kingmed Diagnostics Group Co's ROC (Joel Greenblatt) %, along with its competitors' market caps and ROC (Joel Greenblatt) % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Guangzhou Kingmed Diagnostics Group Co ROC (Joel Greenblatt) % vs Medical Diagnostics & Research Industry
For the Medical Diagnostics & Research industry and Healthcare sector, Guangzhou Kingmed Diagnostics Group Co's ROC (Joel Greenblatt) % distribution charts can be found below:
* The bar in red indicates where Guangzhou Kingmed Diagnostics Group Co's ROC (Joel Greenblatt) % falls into.
Guangzhou Kingmed Diagnostics Group Co ROC (Joel Greenblatt) % Calculation
Joel Greenblatt defined Return on Capital differently in his book The Little Book That Still Beats the Market (Little Books. Big Profits) . He defines Return on Capital as follows:
EBIT stands for Earnings Before Interest and Taxes.
Fixed Assets are also known as non-current assets. They include the Property, Plant and Equipment that the firm needs in its operation.
GuruFocus calculates net working capital as: (Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Deferred Revenue + Other Current Liabilities). We're trying to account for OPERATING assets and liabilities (part of daily business) when calculating working capital. Cash and marketable securities are considered NON-OPERATING assets and are not included in calculation. We will also back out all interest bearing debt, short term debt and the portion of long term debt that is due in the current period from the current liabilities. This debt will be considered when computing cost of capital and it would be inappropriate to count it twice.
Note:
The EBIT data used here is four times the quarterly (Mar. 2026) EBIT data.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
What does a ROC (Joel Greenblatt) % of 6.88% mean?
Guangzhou Kingmed Diagnostics Group Co (SHSE:603882) has a ROC (Joel Greenblatt) % of 6.88% as of Mar. 2026. Joel Greenblatt's return on capital is the ratio of EBIT to average fixed assets and net working capital. View historical data on Guangzhou Kingmed Diagnostics Group Co and its competitors. This is 74% below median its historical median of 26.09. According to the industry distribution chart, Guangzhou Kingmed Diagnostics Group Co ranks #105 out of 210 companies in the Medical Diagnostics & Research industry, placing it in the top 50%.
Is Guangzhou Kingmed Diagnostics Group Co's ROC (Joel Greenblatt) % too high?
Guangzhou Kingmed Diagnostics Group Co's current ROC (Joel Greenblatt) % of 6.88% is 74% below median its 10-year median of 26.09. Based on the distribution chart, Guangzhou Kingmed Diagnostics Group Co ranks #105 out of 210 companies in the Medical Diagnostics & Research industry, which is above the industry midpoint. Overall, Guangzhou Kingmed Diagnostics Group Co has a GF Score™ of 76/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Guangzhou Kingmed Diagnostics Group Co's ROC (Joel Greenblatt) % compare to TMO and DHR?
According to the Medical Diagnostics & Research industry distribution chart, Guangzhou Kingmed Diagnostics Group Co ranks #105 out of 210 companies for ROC (Joel Greenblatt) %. This puts Guangzhou Kingmed Diagnostics Group Co in the upper half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good ROC (Joel Greenblatt) % for a Medical Diagnostics & Research company?
A good ROC (Joel Greenblatt) % depends on the Medical Diagnostics & Research industry context. However, ROC (Joel Greenblatt) % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high ROC (Joel Greenblatt) % mean?
A high ROC (Joel Greenblatt) % can signal that a stock is expensive relative to its fundamentals. Joel Greenblatt's return on capital is the ratio of EBIT to average fixed assets and net working capital. View historical data on Guangzhou Kingmed Diagnostics Group Co and its competitors. Guangzhou Kingmed Diagnostics Group Co's current ROC (Joel Greenblatt) % is 6.88%, which is 74% below median its own 10-year median of 26.09. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Guangzhou Kingmed Diagnostics Group Co stock overvalued right now?
Based on GuruFocus' analysis, Guangzhou Kingmed Diagnostics Group Co (SHSE:603882) is currently considered Fairly Valued. The stock's GF Value™ is ¥28.15, compared to a current price of ¥30.06 — trading 6.8% above its estimated fair value. The current ROC (Joel Greenblatt) % is 6.88%, which is 74% below median its 10-year median of 26.09. Guangzhou Kingmed Diagnostics Group Co's overall GF Score™ is 76/100 with 9 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is ROC (Joel Greenblatt) % calculated?
ROC (Joel Greenblatt) % is calculated from a company's financial statements. For Guangzhou Kingmed Diagnostics Group Co (SHSE:603882), the current ROC (Joel Greenblatt) % is 6.88% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Guangzhou Kingmed Diagnostics Group Co (SHSE:603882) Overvalued in 2026?
Based on GuruFocus' analysis, Guangzhou Kingmed Diagnostics Group Co stock appears to be overvalued.
The current stock price of ¥30.06 is trading 6.8% above its estimated GF Value™ of ¥28.15.
GuruFocus considers Guangzhou Kingmed Diagnostics Group Co to be Fairly Valued.
Key valuation signals for SHSE:603882:
ROC (Joel Greenblatt) %: 6.88% (74% below median its 10-year median of 26.09)
GF Value™: ¥28.15 vs. price of ¥30.06 (6.8% above fair value)
No single metric tells the full story. See the SHSE:603882 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Founded in 1994, KingMed is the largest independent clinical laboratory in China. It was listed on the Shanghai Stock Exchange in 2017. As of 2024, KingMed has 50 centralized labs and provides over 4000 test items. Over 90% of its total revenue comes from clinical diagnostics. Furthermore, KingMed has been actively investing in its cold chain logistics. Its service network covers the most intensely populated areas in China.
76GF Score
Get the complete analysis for SHSE:603882
ROC (Joel Greenblatt) % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
SHSE:603882 has been successfully added to your 
